在晶泰科技的研发助力下，莱芒生物基于其AI+免疫代谢重编程平台，已经开发了多条研发管线。其中 代谢增强型CD19CAR-T疗法，以低至常规CAR-T治疗剂量千分之一(1‰)的极低剂量，实现多位系统性 红斑狼疮患者完全缓解出院(100%CR)，展示了未来"门诊式"CAR-T治疗的全新可能。同时，这一疗法 已助数十位复发难治性白血病/淋巴瘤患者达到CR，并有多个实体瘤领域IIT临床正在开展或即将启动。 值得一提的是，晶泰科技与莱芒生物合作开发了META10-AI平台，结合晶泰科技的AI算法与高通量筛 选实验，对代谢增强型CAR-T疗法中用到的核心代谢增强因子进行了优化设计，使其获得亲和力的数百 倍提高。目前相关结果已经申请中国专利，并应用于实体瘤靶点的代谢增强型CAR-T管线研发中，大幅 提高CAR-T细胞在实体瘤免疫微环境的抗耗竭能力。 晶泰科技(02228)盘中涨近5%，截至发稿，涨3.88%，报13.4港元，成交5.96亿港元。 消息面上，近日，晶泰科技孵化企业莱芒生物在第44届摩根大通医疗健康年会(J.P.Morgan Healthcare Conference)发表演讲，并向全球投资者展示了其极低剂量C ...

Core Insights - The establishment of the Science and Technology Innovation Pilot Zone in Guangxi (Guilin) marks a significant strategic deployment for the region, entering a new phase of comprehensive implementation [1] - The initiative aims to address bottlenecks in technology transfer, innovation capabilities, and collaborative openness in Guangxi, positioning Guilin as a hub for innovation and technology cooperation with ASEAN [2][3] Group 1: Reasons for Establishment - The pilot zone is designed to create a unique innovation path tailored to Guangxi's realities, facilitating a full chain from basic research to market application [2] - Guilin's strong educational and industrial foundation, including 16 higher education institutions and 10 prominent research institutes, supports its selection as the pilot zone [3][4] Group 2: Industrial Foundation - Guilin has developed a modern industrial system focusing on information technology, advanced manufacturing, biomedicine, and other key sectors, with significant technological achievements [6] - The optical electronics industry is projected to achieve over 5 billion yuan in output by 2025, reflecting a 40% year-on-year growth [6] Group 3: Innovation Ecosystem - The city is actively building a comprehensive ecosystem for technology transfer and innovation, including alliances with universities and research institutions [7] - The establishment of high-energy innovation parks and collaboration with external quality innovation service organizations is underway [7] Group 4: Action Plan and Goals - By 2030, the pilot zone aims to significantly enhance innovation capabilities, increase R&D investment intensity to over 2%, and boost the number of high-tech enterprises [8][9] - Five major actions will be implemented to achieve these goals, including the construction of high-energy innovation parks and the promotion of technology transfer [9][10] Group 5: Reform and Implementation - The initiative will explore reforms in technology systems, focusing on rights distribution, talent evaluation, and error tolerance to stimulate innovation [11] - Key performance indicators will be established for 2026, with a focus on R&D investment, enterprise cultivation, and industrial growth [11]

Core Insights - The city has officially released a list of 516 major economic and social development projects for 2026, with a total planned investment that has increased by 1.2% year-on-year [1] Group 1: Project Overview - A total of 479 projects are set for implementation, including 160 new projects, while 37 projects are in the preliminary stage [1] - The list signals a strong commitment to stabilize expectations and boost confidence in economic development [1] Group 2: Dual-Driven Development - Among the implemented projects, 392 are industrial projects, including 59 in scientific innovation, 254 in advanced manufacturing, 78 in modern services, and 1 in modern agriculture, alongside 87 infrastructure and social welfare projects [2] - Industrial investment is the main driver, with a year-on-year increase of 6.8% in planned investment for industrial projects [2] - Notable growth is seen in the new electronic information industry and high-end intelligent equipment industry, with increases of 19.6% and 15.1% respectively [2] Group 3: Industry Upgrades - Advanced manufacturing projects include 35 in new electronic information, 27 in green intelligent vehicles, 87 in high-end intelligent equipment, 26 in biomedicine, and 29 in petrochemicals and new materials [3] - The focus on key sectors aligns with the city's strengths, showcasing a trend towards higher and newer industrial development [3] - Significant projects like the Xunlian hydraulic products project, with a total investment of approximately 1 billion yuan, aim to enhance industrial cluster capabilities [3] Group 4: Infrastructure and Social Welfare - The construction of the Nanjing North Station is progressing, with completion expected by October 2027, which will significantly impact regional connectivity and economic development [4][5] - Major projects include significant transportation infrastructure and urban renewal initiatives, aimed at enhancing urban vitality and living quality [5] - The city plans to optimize service guarantees to ensure projects start early, are built quickly, and yield results promptly, supporting high-quality economic and social development [5]

Group 1 - The core viewpoint of the news highlights the positive performance of the medical and healthcare innovation sector, with the China Medical and Medical Device Innovation Index rising by 0.87% and several key stocks showing significant gains [1] - Over 50 biopharmaceutical companies have disclosed their 2025 performance forecasts, with nearly half (27 companies) expecting positive results, indicating a favorable outlook for the sector [1] - The CXO (Contract Research Organization) industry, particularly leading company WuXi AppTec, is projected to achieve approximately 45.46 billion yuan in revenue for 2025, reflecting a year-on-year growth of about 15.84%, and a net profit increase of approximately 102.65% [1] Group 2 - The National Healthcare Security Administration has introduced new policies to accelerate the promotion and adoption of surgical robots and related surgical consumables, which is expected to benefit the overall innovative medical device market [2] - Investors are advised to focus on two main investment themes: the surgical robot industry and its supply chain, as well as high-value consumables in minimally invasive surgery, orthopedics, gastroenterology, cardiovascular, and neurology [2] - The China Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability and growth potential, with the top ten stocks accounting for 63.75% of the index [2]

Core Viewpoint - *ST Bio is facing significant challenges, including delisting risks, performance volatility, and uncertainties surrounding its restructuring efforts, leading to a sharp decline in stock price and investor confidence [2]. Group 1: Company Fundamentals - *ST Bio's stock hit the limit down price of 8.84 yuan, with a decline of 4.95%, resulting in a total market capitalization of 29.17 billion yuan and a circulating market value of 29.09 billion yuan [1]. - The company is undergoing a critical phase of business transformation and financial restructuring, with expected profitability and substantial revenue growth in 2025, but 2024 financial indicators trigger delisting risk warnings [2]. - The company is projected to incur a net loss in 2024, with significant performance fluctuations and a high proportion of non-recurring gains, alongside rising debt levels, which are undermining market confidence [2]. Group 2: Restructuring and Market Sentiment - The major asset restructuring is currently in the planning stage, with uncertainties regarding its implementation, leading to skepticism about the restructuring's effectiveness and negatively impacting investor confidence [2]. - The newly introduced "yesterday's limit-up" concept lacks sustainability and fails to have a substantial impact on the company's fundamentals, which does not support the stock price [2]. - The competitive landscape in the biopharmaceutical industry poses risks for the company's business integration, and the performance contribution from the newly acquired Jin Hong New Materials remains to be observed [2]. Group 3: Technical and Financial Aspects - Due to the numerous uncertainties faced by the company, there may be a potential outflow of funds, which could lead to technical indicators such as MACD crossovers and BOLL channel breakdowns, further exacerbating stock price declines [2].

Report Industry Investment Rating No relevant content provided. Core Viewpoints of the Report - In 2026, the world will be in a macro - background of deepening "de - globalization" and the resonance of loose fiscal policies of major economies. Supply - chain vulnerability and demand expansion will lead to a tightening of resource supply - demand relations, and intensify strategic competition for key minerals and energy [1]. - China's economy will be based on the principle of "internal stability and external control" in 2026. Exports will remain a mainstay, investment will play a supporting role, and consumption will focus on equipment updates and service - scenario innovation. The de - dollarization trend and the weakening of the US dollar credit will bring opportunities for international capital inflows into RMB assets, and Sino - US competition will focus on technology and supply - chain security [1]. - In 2026, a macro - hedging portfolio should be constructed under the premise of seeking certainty. Commodity assets will have prominent allocation value, with the order of commodity > equity > bond. Attention should be paid to potential uncertainties such as recessions in Europe and the US, domestic inflation repair, geopolitics, and real - estate risks [2]. Summary by Directory I. Cycle Changes: Resonance of "De - globalization" and Loose Fiscal Policies (1) The Wave of De - globalization: From Great - Power Games to the G2 Pattern - International events such as the COVID - 19 pandemic, the Russia - Ukraine war, and the Trump administration's high - tariff policies have led to the wave of de - globalization, which is essentially the reshaping of the world order [6]. - Traditional capitalist powers like the US and the UK are withdrawing from international alliances, while emerging - market countries led by China are exploring new international cooperation models. A G2 competition pattern between China and the US is gradually taking shape in key technologies and resources [7]. - The wave of de - globalization has increased the vulnerability of the global supply chain, deteriorated the global trade environment, and accelerated the rotation and increased the volatility of global major assets. The credit systems of the US dollar and US Treasury bonds have been shaken [9]. (2) Loose Fiscal Resonance: Upward Global Manufacturing and Inventory Cycles - In 2026, the fiscal policies of major overseas economies such as the US, Europe, and Japan are expected to expand further. The US "big and beautiful" bill may increase the fiscal deficit by $4.1 trillion in the next decade, and EU countries will increase their defense spending to 5% of GDP by 2035. Japan will implement a trillion - level economic stimulus plan. This will lead to an increase in economic activity demand and drive up the global manufacturing and inventory cycles [15]. (3) Resource Shortage: Tightening Supply - Demand Balance - De - globalization has increased supply - chain vulnerability, and loose fiscal policies will stimulate demand, leading to a tightening of the global industrial supply - demand relationship. Countries will pay more attention to resource competition for national security. The US is seizing resources through trade control and military actions. Core resources such as minerals and energy will see price increases in 2026 [16]. II. The Game between Endogenous Momentum and External Changes (1) Endogenous Economic Transformation: Long - Term Policy Guidance of the 15th Five - Year Plan - In 2026, as the starting year of the 15th Five - Year Plan, China aims to achieve a reasonable GDP growth rate while gradually realizing structural transformation. New - quality productivity sectors such as AI, biomedicine, and new energy will become new pillar industries [17]. - Investment will be the supporting force for achieving economic growth goals, while consumption will be the main growth driver. Exports will remain a mainstay due to factors such as reduced Sino - US trade - dispute volatility, fiscal expansion in developed economies, and the rise of emerging markets. Investment in infrastructure, manufacturing, and new areas will support economic growth, and real - estate's negative impact on the economy is expected to turn neutral [18][19][23]. - In the consumption area, policies will focus on releasing existing demand through subsidies and exploring incremental demand by expanding service - consumption scenarios [27]. (2) External Changes and Game: Coexistence of Challenges and Opportunities - The weakening of the US dollar credit due to the expiration of the "petro - dollar" agreement and the establishment of a new cross - border settlement mechanism provides an opportunity for RMB assets. International capital will flow back to the Asia - Pacific market and drive up the prices of RMB - denominated assets. China can promote RMB internationalization [30]. - Sino - US relations will remain a key variable in 2026. The two countries have long - term competition and phased balance in technology and resource issues. The competition pattern will not change significantly, and extreme decoupling is unlikely [31]. III. Guidance on Major Asset Allocation: Constructing a Macro - Hedging Portfolio (1) Between "Change and Constancy": Unchanging Competition Relations and Changing Cycle Rotations - The long - term competition exists among all global economies due to limited resources and growing economic demand. China's economic recovery has three main lines: technological independence, price repair, and expansion of domestic demand. The US will try to avoid recession and stagflation, and continue to rely on the stock market and AI to support the economy [33]. (2) 2026: Seeking Certainty and Constructing a Major Asset Portfolio: Commodity > Equity > Bond - In 2026, asset allocation should pursue certainty and balance risks. Attention should be paid to risks such as recessions in Europe and the US, slow domestic inflation repair, intensified de - globalization, and a downward real - estate market [36]. (3) Grasping the Rhythm and Main Lines in the Short, Medium, and Long Terms - Based on economic - cycle theory, in the high - inflation and high - growth stage (2026 - 2027 expected), commodities will be dominant. Different commodity sectors will rotate in the order of risk pricing, expected trading, and real - situation regression [37]. - In 2026, the four quarters will be dominated by different factors: Q1 is dominated by short - term liquidity, driving up the prices of precious metals and non - ferrous metals; Q2 focuses on correcting the mid - term narrative; Q3 verifies the long - term logic; Q4 is for brewing cross - year expectations [39].

Core Viewpoint - *ST生物 has announced the termination of its major asset restructuring plan, which was initially aimed at acquiring a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. The termination was agreed upon by all parties involved after failing to reach a substantial agreement during negotiations [1][3]. Group 1: Termination of Restructuring - The company disclosed the termination of the major asset restructuring plan on January 22, 2026, after multiple negotiations failed to yield an agreement [1][3]. - The restructuring plan was first announced on August 12, 2025, but did not progress to the formal implementation stage [1]. Group 2: Impact on Operations - The termination of the restructuring will not have a significant adverse impact on the company's current operations or financial status [3]. - The company maintains that the termination does not harm the interests of shareholders, particularly minority shareholders [3]. Group 3: Financial Performance Forecast - *ST生物 expects its 2025 revenue to be between 385 million to 425 million yuan, with a significant increase from approximately 130 million yuan in the previous year [3]. - The company forecasts a total profit of 18.5 million to 26.5 million yuan for 2025, with net profit attributable to shareholders expected to be between 28.5 million to 32.5 million yuan [3]. - All financial indicators are projected to show a turnaround, with net profit after excluding non-recurring gains and losses estimated between 8.5 million to 12.5 million yuan [3].

Core Viewpoint - Suzhou Industrial Park is embarking on a new industrialization journey centered around "AI + Manufacturing," demonstrating strategic determination and continuous innovation in the face of global manufacturing intelligence trends [1] Group 1: Industrial Development Strategy - The park has focused on new industrialization for three consecutive years, maintaining its commitment to "industrial-based region, manufacturing-strong region" while adapting its tactical approach based on technological and industrial upgrades [1] - The strategic progression consists of three phases: the first phase emphasized "intelligent transformation and digitalization," the second phase focused on "strengthening the industrial chain," and the third phase aims for deep integration of "AI + manufacturing" to enhance quality and efficiency [1] Group 2: Economic Performance - The industrial economy of the park has accelerated, with the total industrial output value surpassing 600 billion and 700 billion, projected to reach 736.2 billion by 2025, with an average annual growth rate of 6.8% [2] - High-tech industries account for 72.5% of the total industrial output value, showcasing strong growth potential [2] - The park has nurtured 7 industrial enterprises with over 10 billion in revenue, 72 listed companies, and over 3,200 national high-tech enterprises, forming a robust enterprise ecosystem [2] Group 3: AI Integration and Future Plans - The park aims to achieve an industrial output value exceeding 770 billion this year, focusing on smart, green, and integrated development across five dimensions: industrial quality and efficiency, enterprise development capability, technological innovation, "AI +" initiatives, and green development [3] - The transition from "adding AI" to "AI-driven" signifies a shift in competitive focus from individual factory intelligence to the overall regional industrial ecosystem leveraging AI for systemic transformation [3] Group 4: Policy Framework and Implementation - A comprehensive policy framework supporting "AI + manufacturing" has been established, including action plans and measures to drive the development of AI in manufacturing [4][5] - The policy emphasizes "scene-driven" and "element support" strategies, facilitating real manufacturing scenarios to uncover AI needs and enhance innovation ecosystems [4][5] Group 5: Case Studies and Industry Impact - Companies like Suzhou YR Technology have successfully scaled from millions to billions in revenue by deeply integrating AI into their manufacturing processes, demonstrating the potential of AI in enhancing productivity [5] - AI companies in the park, such as Sobot, are leveraging their technological innovations to empower various industries, with expectations of significant revenue growth in the coming years [5]

Group 1 - The three major indices collectively rose, while the National Securities Biopharmaceutical Index (399441) fell by 0.84%. Among its constituent stocks, Kanglong Chemical rose over 1%, Hualan Biological increased by 0.59%, Tigermed gained 0.52%, and Jianfan Biological was up by 0.5% [1] - The Biopharmaceutical ETF (159859) had a trading volume of 100 million yuan yesterday, ranking first among similar products. According to Wind data, the ETF saw a net subscription of over 130 million shares yesterday [1] - As of January 21, the Biopharmaceutical ETF experienced a net inflow of 23.95 million yuan, marking three consecutive trading days of net inflows, with a cumulative net inflow of 116 million yuan [1] Group 2 - The Biopharmaceutical ETF closely tracks the Biopharmaceutical Index, which is based on A-share listed companies in the biopharmaceutical industry, selecting the top 30 stocks based on market capitalization and liquidity [1] - Nine departments, including the Ministry of Commerce and the National Development and Reform Commission, jointly issued opinions to promote high-quality development in the pharmaceutical retail industry, proposing 18 specific measures [1] - According to Pacific Securities, the biopharmaceutical industry will enter a critical phase of innovation realization and global layout by 2026, supported by the synergy of industry, policy, and capital [2]

Core Viewpoint - The article highlights the successful fundraising of Hengxu Capital's fourth flagship fund, which raised over 2 billion RMB in its first closing, indicating a strong start to the new year and showcasing the firm's unique position in the private equity market as a market-oriented corporate venture capital (CVC) with substantial industry background and resources [2][3]. Fundraising and LP Structure - Hengxu Capital's fourth flagship fund received continued support from significant shareholders such as SAIC Group and various financial institutions, along with strong backing from local governments in the Yangtze River Delta [3]. - The fund has innovatively split into two sub-funds based in Changzhou and Ningbo to better address the diverse needs of different LPs, aiming to create a comprehensive investment ecosystem that covers the entire lifecycle of innovative enterprises [3][4]. Regional Cooperation and Project Development - In Changzhou, local governments have actively participated in the fund, reflecting their recognition of Hengxu Capital's past performance and unique empowerment model, which has facilitated the landing of major projects [4]. - In Ningbo, the fund has attracted multiple large industrial projects due to the region's favorable business environment and efficient communication during the fund establishment process [6]. Investment Strategy and Focus Areas - Hengxu Capital plans to leverage its experience in complex industrial chain investments to expand into broader hard technology sectors, including artificial intelligence, semiconductors, aerospace, quantum technology, nuclear energy, and biomanufacturing [9]. - The firm aims to act as an industrial enabler, not just providing capital but also connecting technology, manufacturing, and market needs [9]. Performance and Exit Strategy - In the past year, Hengxu Capital successfully exited 12 projects through various means, with over 30 invested companies achieving subsequent financing and valuation growth, showcasing its strong exit capabilities and return potential [9][10]. Investment Activity and Portfolio - In 2025, Hengxu Capital invested nearly 1.4 billion RMB across 19 projects, with over 20% of investments in early-stage projects, marking a strategic shift from automotive to emerging industries and health consumption [10]. - The firm has made significant investments in various sectors, including embodied intelligence and semiconductor technology, demonstrating its proactive approach to identifying high-potential projects [11][12]. Long-term Vision and Ecosystem Development - Hengxu Capital aims to become one of the most market-oriented industrial capital entities, focusing on independent judgment and financial returns while leveraging its industry insights and resources to create strategic co-creation capabilities across diverse fields [13]. - The firm has established a comprehensive empowerment system covering post-investment management, talent acquisition, follow-up financing, and IPO planning, enhancing the competitive advantages of its portfolio companies [14][15]. Future Outlook - Hengxu Capital is well-positioned to capitalize on the historical opportunities presented by the convergence of policy, capital, and technology in the hard technology sector, as it prepares for future investments and strategic developments [16].